Stoke Therapeutics (STOK)
(Delayed Data from NSDQ)
$14.63 USD
+0.38 (2.67%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $14.64 +0.01 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Price, Consensus and EPS Surprise
STOK 14.63 +0.38(2.67%)
Will STOK be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for STOK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for STOK
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?
STOK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
Other News for STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Commit To Purchase Stoke Therapeutics At $12.50, Earn 27.6% Annualized Using Options
Buy Rating for Stoke Therapeutics: FDA Progress and Strong Financials Underpin Future Potential
Buy Rating Affirmed for Stoke Therapeutics Amid Solid Q2 Performance and Regulatory Progress
Stoke Therapeutics: A Strong Buy on Promising Drug Developments and Potential Clinical Breakthroughs